Lumida
/ANIK
⌘K
Anika Therapeutics Inc

Anika Therapeutics Inc

ANIK
$20.99USD↑+0.53%+0.11 today

MARKET CAP

280.9M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$21 – $21

52W RANGE

$8
$23

AI Summary

Stalk
Sell NowMedium

ANIK is in a Stage 3 distribution phase, granting bearish medium-term permission. Short-term price is rejecting around the 9/21 EMAs and 50-day SMA, reflecting diminishing demand and structure failure. The preferred execution is selling into rallies near these resistance zones, aligning with the dominant downtrend while respecting potential short-term oversold bounces.

  • ↑Q2 revenue rose 16% YoY to $32.6M, led by 17% commercial growth
  • ↑Gross margin reached 65%, highest since 2020, driving profitability
  • ↓OEM channel revenue down 17% YoY, highlighting pricing pressure from partners
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Anika Therapeutics, Inc. (NASDAQ: ANIK) is a biotechnology company that specializes in developing and commercializing innovative hyaluronic acid-based solutions for osteoarthritis pain and regenerative medicine. The company is significant in the orthopedic sector, focusing on non-surgical treatments, particularly through its flagship products Integrity and HylaFast. Anika aims to capitalize on the growing demand for regenerative therapies amid a global trend toward effective non-invasive treatment options.

Bull says

  • ↑Q2 revenue rose 16% YoY to $32.6M, led by 17% commercial growth
  • ↑Gross margin reached 65%, highest since 2020, driving profitability
  • ↑Adjusted EBITDA at $7.1M; $15M share buyback reflects capital discipline
  • ↑Integrity product growth at 39% YTD; now used by 300+ surgeons
  • ↑Insider purchases of $20.8K and analyst upgrades to Strong-Buy indicate confidence
  • ↑Favorable factor profile: high earnings yield, strong growth, positive revisions

Bear says

  • ↓OEM channel revenue down 17% YoY, highlighting pricing pressure from partners
  • ↓FDA approval for HylaFast remains undetermined, risking delayed product launches
  • ↓Negative dividend yield underscores limited capital returns and potential cash-flow constraints
  • ↓High short interest and negative momentum factors indicate investor skepticism
  • ↓Small company size heightens vulnerability to macroeconomic swings
  • ↓Regulatory and pricing headwinds may curb future margin expansion

Earnings Call · Q2 2025 · Mgmt. Guidance

Updated 08-12-2026neutral

Transcript signals

Bull points

  • regenerative solutions delivered standout performance, growing 41% year over year, driven by continued momentum in the integrity and plant system.
  • Importantly, integrity has now achieved sequential growth for five consecutive quarters, and as of June, we've already exceeded full year 2024 revenue for the product, on track to more than double in 2025.
  • our teams are working diligently to fulfill backlog distributor orders and expect to recover these orders in the third quarter.

Bear points

  • $28.2 million in total revenue, an 8% decline compared to the same period in 2024.
  • We anticipate a pricing decline in Q3, followed by a modest rebound in the fourth quarter, with no change to our full-year pricing outlook.
  • $18.5 million, down $3.8 million or 17% compared to the same period last year.
Read full transcript analysis ›